Tag Archives: China Approves GSK’s Nucala to Reduce Exacerbations in Adults with COPD

GSK Secures China Approval for Nucala in Broad COPD Patient Population

Posted on 5, January 2026 by EuropaWire PR Editors

(IN BRIEF) GSK has received approval from China’s National Medical Products Administration for Nucala as an add-on maintenance therapy for adults with inadequately controlled COPD and elevated blood eosinophils. Supported by positive MATINEE and METREX phase III trial data, the … Read the full press release →

Posted in Business, Healthcare, Pharma & Biotech, Science, Technology, United Kingdom

Tagged biologic therapy, blood eosinophil count, China Approves GSK’s Nucala to Reduce Exacerbations in Adults with COPD, China NMPA approval, Chronic obstructive pulmonary disease, COPD treatment, eosinophilic COPD, exacerbation reduction, GSK, IL-5 monoclonal antibody, Kaivan Khavandi, MATINEE trial, mepolizumab, METREX trial, Nucala, respiratory medicine